Is there a role for neoadjuvant chemotherapy in upper-tract urothelial carcinoma?  

Since the benefit of neoadjuvant chemotherapy is well-defined in muscle-invasive bladder cancer, is it reasonable to consider this in upper-tract tumors as well?  Are there particular subgroups of patients who may be most appropriate?



Answer from: Medical Oncologist at Academic Institution